Treatment of myelodysplastic syndrome with a DNA methyltransferase inhibitor: Lack of evidence for induction of chromosomal instability

Leukemia Research

Volumn 30, Issue 3, 2006, Pages 338-342

  Haas, Peter S ^a   Wijermans, Pierre ^b   Verhoef, Gregor ^c   Lübbert, Michael ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b LEYENBURG HOSPITAL   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Decitabine; DNA methylation; Myelodysplasia

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA METHYLTRANSFERASE INHIBITOR;

ADULT; AGED; ARTICLE; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME LOSS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; KARYOTYPING; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METAPHASE; MOLECULAR CLONING; MYELODYSPLASTIC SYNDROME; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEQUENTIAL ANALYSIS;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CHROMOSOMAL INSTABILITY; CHROMOSOME DELETION; CYTOGENETIC ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METAPHASE; MIDDLE AGED; MONOSOMY; MYELODYSPLASTIC SYNDROMES;

EID: 30144439553     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.07.014     Document Type: Article

References (20)

1. D. Gius, H. Cui, C.M. Bradbury, J. Cook, D.K. Smart, and S. Zhao Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach Cancer Cell 6 4 2004 361 371
2. P.A. Jones, and S.B. Baylin The fundamental role of epigenetic events in cancer Nat Rev Genet 3 2002 415 428
3. L.R. Silverman, E.P. Demakos, B.L. Peterson, A.B. Kornblith, J.C. Holland, and R. Odchimar-Reissig Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B J Clin Oncol 20 2002 2429 2440
4. P.W. Wijermans, J.W. Krulder, P.C. Huijgens, and P. Neve Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome Leukemia 11 1 1997 1 5
5. P. Wijermans, M. Lübbert, G. Verhoef, A. Bosly, C. Ravoet, and M. Andre Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients J Clin Oncol 18 5 2000 956 962
6. A.B. Kornblith, J.E. Herndon II, L.R. Silverman, E.P. Demakos, R. Odchimar-Reissig, and J.F. Holland Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study J Clin Oncol 20 10 2002 2441 2452
7. Yang AS, Estecio MR, Garcia-Manero G, Kantarjian HM, Issa JP. Comment on "Chromosomal instability and tumors promoted by DNA hypomethylation" and "Induction of tumors in mice by genomic hypomethylation". Science 2003; 302(5648):1153; author reply 1153, 2003 Nov 14 [Comment: Journal Article].
8. P.W. Laird, L. Jackson-Grusby, A. Fazeli, S.L. Dickinson, W.E. Jung, and E. Li Suppression of intestinal neoplasia by DNA hypomethylation Cell 81 1995 197 205
9. F. Gaudet, J.G. Hodgson, A. Eden, L. Jackson-Grusby, J. Dausman, and J.W. Gray Induction of tumors in mice by genomic hypomethylation Science 300 2003 489 492
10. M. Ehrlich The ICF syndrome, a DNA methyltransferase 3B deficiency and immunodeficiency disease Clin Immunol 109 1 2003 17 28
11. C. Lengauer Cancer: an unstable liaison Science 300 2003 442 443
12. Wijermans PW, Lübbert M, Verhoef G, Klimek V, Bosly A. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'′-deoxycytidine (Decitabine) in 177 patients. Ann Hematol 2005, in press.
13. G. Tricot, M.A. Boogaerts, C. De Wolf-Peeters, H. Van den Berghe, and R.L. Verwilghen The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations Br J Haematol 59 4 1985 659 670
14. S. Horiike, M. Taniwaki, S. Misawa, and T. Abe Chromosome abnormalities and karyotypic evolution in 83 patients with myelodysplastic syndrome and predictive value for prognosis Cancer 62 1988 1129 1138
15. H.M. Ghaddar, S.A. Stass, S. Pierce, and E.H. Estey Cytogenetic evolution following the transformation of myelodysplastic syndrome to acute myelogenous leukemia: implications on the overlap between the two diseases Leukemia 8 10 1994 1649 1653
16. J. Benitez, E. Valcarcel, C. Ramos, C. Ayuso, and A.S. Cascos Frequency of constitutional chromosome alterations in patients with hematologic neoplasias Cancer Genet Cytogenet 24 2 1987 345 354
17. M. Lübbert, P. Wijermans, R. Kunzmann, G. Verhoef, A. Bosly, and C. Ravoet Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′- deoxycytidine Br J Haematol 114 2001 349 357
18. V. Parlier, G. van Melle, P. Beris, P.M. Schmidt, A. Tobler, and E. Haller Hematologic, clinical, and cytogenetic analysis in 109 patients with primary myelodysplastic syndrome Prognostic significance of morphology and chromosome findings Cancer Genet Cytogenet 78 2 1994 219 231
19. A.A Geddes, D.T. Bowen, and A. Jacobs Clonal karyotype abnormalities and clinical progress in the myelodysplastic syndrome Br J Haematol 76 2 1990 194 202
20. J. Benitez, F. Carbonell, J. Sanchez Fayos, and H. Heimpel Karyotypic evolution in patients with myelodysplastic syndromes Cancer Genet Cytogenet 16 2 1985 157 167